

# Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma

Noriaki Arakawa,<sup>1,2</sup>§ Etsuko Miyagi,<sup>3</sup> Ayako Nomura,<sup>2</sup> Erina Morita,<sup>1</sup> Yoko Ino,<sup>2</sup> Norihisa Ohtake,<sup>4</sup> Yohei Miyagi,<sup>5</sup> Fumiki *Hirahara*,<sup>3</sup> and Hisashi Hirano<sup>1,2</sup>§

<sup>1)</sup> Department of Medical Life Science, Graduate School of Medical Life Science,

Yokohama City University, Yokohama, Kanagawa, Japan

<sup>2)</sup> Advanced Medical Research Center, Yokohama City University,

Yokohama, Kanagawa, Japan

<sup>3)</sup> Department of Gynecology, Yokohama City University Graduate School of Medicine,

Yokohama, Kanagawa, Japan

<sup>4)</sup> Bioscience Division, Reagent Development Department, Tosoh Corporation,

Ayase, Kanagawa, Japan

<sup>5)</sup> Research Institute, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan

**Keywords:** Ovarian cancer / Clear cell adenocarcinoma / Biomarker / Diagnosis / TFPI2

**Corresponding Author:** Noriaki Arakawa and Hisashi Hirano

Tel: +81-45-787-2322; Fax: +81-45-787-2787

"mailto:arakawa@yokohama-cu.ac.jp"

Department of Medical Life Science, Graduate School of Medical Life Science, Yokohama City University, 3-9, Fukuura, Kanazawa, Yokohama, Japan, 236-0004

## **ABSTRACT**

Of all of the epithelial ovarian cancers (EOC), clear cell adenocarcinoma (CCA) has the worst clinical prognosis. Furthermore, the conventional EOC biomarker CA125 is more often negative in CCA than in other subtypes of EOC. This study sought to discover a new diagnostic biomarker that would allow more reliable detection of CCA. Using mass spectrometry, we compared proteins in conditioned media from cell lines derived from CCA and other types of EOC. We identified 30 extracellular or released proteins specifically present in CCA-derived cell lines. Bioinformatics analyses identified a serine protease inhibitor, tissue factor pathway inhibitor 2 (TFPI2), as a potential biomarker for CCA. Real time RT-PCR and Western blot analyses revealed that TFPI2 was exclusively expressed in CCA-derived cell lines and tissues. For clinical validation, we measured levels of TFPI2 and CA125 in a set of sera from 30 healthy women, 30 patients with endometriosis, and 50 patients with CCA, using an automated enzyme-linked immunosorbent assay (ELISA) systems. Serum levels of TFPI2 were significantly elevated in CCA patients, even those with normal CA125 levels. In terms of area under the receiver operating characteristic curve (AUC), TFPI2 was superior to CA125 in discriminating CCA patients from healthy women

(AUC 0.97 for TFPI2 versus AUC 0.80 for CA125), or from patients with endometriosis (AUC 0.93 for TFPI2 versus 0.80 for CA125). This is the first evidence for TFPI2 as a serum biomarker of CCA. We propose that this biomarker may be useful for detection of CCA and for monitoring the transformation from endometriosis into CCA.

## Introduction

Ovarian cancer is a leading cause of death among gynecological malignancies. Epithelial ovarian cancer (EOC), which represents the majority of ovarian cancers, is both morphologically and biologically heterogeneous<sup>1</sup>. Among EOC subtypes, ovarian clear cell adenocarcinoma (CCA) is a highly malignant histological type of EOC. More patients with CCA are diagnosed during stage I than patients with other types of EOC; however, they exhibit weaker responses to standard platinum-based chemotherapy, resulting in worse clinical prognoses.<sup>2</sup> Recurrence of CCA is higher than other types of EOC, even in early stages.<sup>3</sup> CCA cells exhibit relatively low proliferation activity, providing one explanation of the weak response to chemotherapy.<sup>4,5</sup> Therefore, earlier diagnosis and monitoring of CCA are vital.

Currently, cancer antigen 125 (CA125/MUC16) is the most frequently used clinical biomarker for EOC. However, CA125 is often negative in the early stages of EOC (only 23% positive in stage I, in contrast to more than 80% in advanced EOC).<sup>6</sup> Even though CA125 correlates with late-stage serous-type EOC, it is not a reliable marker for CCA: CA125 is frequently present at normal levels even at advanced stages of CCA.<sup>7, 8</sup> Furthermore, elevation of CA125 level is also observed in benign tumors such as endometriosis,<sup>9</sup> which is thought to be a risk factor of CCA.<sup>10</sup> Therefore, the identification of new biomarker is needed to detect of CCA efficiently.

Proteomics technology allows the high-throughput identification of thousands of proteins in complex mixtures. This technology has been applied to cancer biomarker discovery. Comprehensive proteome analyses using CCA-derived cell lines and tissues have identified several CCA-associated proteins, including annexin A4.<sup>11,12</sup> However, very few of the proteins identified in this manner have been shown to be serum/plasma markers potentially useful for diagnosis of CCA. To identify optimal biomarkers, it is important to

consider whether the proteins of interest can actually be detected in serum/plasma samples. Furthermore, identification of biomarkers from serum or plasma using proteomics technology also has inherent limitations. Serum/plasma proteomes predominantly consist of highly abundant proteins, including albumin and immunoglobulins, which represent over 90% of the identifiable proteins within such samples. Even after depletion of the highly abundant proteins and extensive fractionation, characterization of the low-abundance proteins remains difficult.<sup>13</sup>

The diverse set of proteins secreted or released from cells, including proteins shed from their surface, is referred to as the “secretome”. In cancer progression, multiple characteristic proteins are released from tumor cells. These proteins include growth factors and cytokines, which play important roles in cell signaling, communication, and migration. Many of these proteins enter the circulation, allowing them to be detected in patient blood samples. Thus, secretome proteins are likely to be useful as diagnostic markers of cancer.<sup>14</sup>

In this study, we performed secretome analysis of CCA-derived cell lines in order to discover novel clinical biomarkers that are specific to CCA, i.e., not expressed in cell lines derived from other types of EOC. In our bioinformatics analysis, we identified tissue factor pathway inhibitor 2 (TFPI2), a serine protease inhibitor, as a potential biomarker. This protein was validated as a serum marker in patients with CCA.

## **Material and methods**

*Ovarian cancer cell lines*—CCA-derived cell lines, OVTOKO, OVISE, OVMANA, and OVSAYO, and ovarian serous adenocarcinoma-derived cell lines, OVSAHO and OVKATE were established as described previously.<sup>15,16</sup> Ovarian mucinous adenocarcinoma-derived cell lines, RMUG-S and MCAS were purchased from the Japanese Collection of Research Bioresources (JCRB, Osaka, Japan). All cell lines were maintained in RPMI1690 medium (Nacalai tesque, Kyoto, Japan) containing 10% fetal bovine serum (FBS, Gibco) in a humidified incubator at 37°C under 5% CO<sub>2</sub>. The cultures were maintained for no more than 10 passages after recovery from frozen stocks.

*Sample preparation for proteomic analysis*—For secretome analysis, the media were replaced with serum-free media supplemented with 4 nM epidermal growth factor (Invitrogen, Carlsbad, CA). After incubation for 48 h, conditioned media were collected and lyophilized. The lyophilized media were dissolved in 2 mL of 10 mM ammonium bicarbonate containing 4 M urea, and proteins were precipitated with acetone for de-salting and concentration. Precipitated protein was resuspended with 10 mM ammonium bicarbonate containing 4 M urea and 0.1% RapiGest detergent (Nihon Waters, Tokyo, Japan), and used for proteomic analysis. Protein samples from serous-type cell lines (OVSAHO and OVKATE) or mucinous-type cell lines (RMUG-S and MCAS) were combined such that each pooled sample contained equal quantities of protein. The mixed samples and individual samples from CCA cell lines were used for proteomic analysis.

*Proteomic analysis*—Protein (10 µg) was reduced with 10 mM DTT, and then alkylated with 25 mM iodoacetamide. The resulting alkylated protein was digested with trypsin

overnight at 37°C. Peptides were analyzed using an LC-MS/MS system consisting of a reverse-phase (RP) LC and an LTQ Orbitrap mass spectrometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). Peptides from 3 µg of protein were analyzed in each run; this analysis was repeated three times per sample.

RPLC was performed in a 115-min acetonitrile gradient (4–40%). The RPLC effluent was interfaced with an electrospray ionization source in positive ion mode on the mass spectrometer. Protonated peptides were analyzed sequentially for MS/MS in Data-Dependent Scanning mode, consisting of a full-range scan at an m/z range of 350–1,200 and subsequent product ion scans for each of the three most intense ions in the full-scan mass spectrum. Data analysis was performed using the Proteome Discoverer 1.3 software (Thermo Scientific) with Mascot ver. 2.3.02 (Matrix Science, London, UK). The peptide mass tolerance was set to 3 ppm and 0.5 Da for MS/MS fragmentation ions. Trypsin was set as the protease with two missed cleavage sites allowed. Cysteine carbamidomethylation and methionine oxidation were searched as a variable modification. MS/MS data were used to search for corresponding amino-acid sequences in the Swiss-Prot database (<http://expasy.org/sprot>). All spectra were queried against the target/decoy database to achieve a targeted false-discovery rate of 1% for all samples, using the Proteome Discoverer software.

*Tissues and sera*—This study included a total of twelve tissue samples taken from four patients with CCA, four patients with other ovarian cancers, and four patients with malignant tumors, treated between 2002 and 2005. These tissue samples were taken from freshly isolated surgical resections in the operating room, rinsed thoroughly with saline, and snap-frozen in liquid nitrogen. Frozen tissues were stored at -80°C until use. Documented informed consent was obtained from each patient, and the study was performed in accordance with the guidelines of the Ethical Committee of Yokohama City University Graduate School

of Medicine. All cases were reviewed and histopathologically diagnosed by a pathologist. These tissue samples were used for *TFPI2* gene-expression analyses. In addition, commercially available total RNA samples from normal ovaries were purchased from Zyagen Laboratories (San Diego, CA, USA) and Ambion (Austin, TX, USA) and used as healthy controls in the gene-expression analyses. The corresponding clinicopathological data are shown in Table 2.

For the serum TFPI2 assay, a total of 110 female serum samples (collected between 1989 and 2011) were obtained from the following bioresource banks: 50 sera from patients with CCA were obtained from SLR Research Corporation (Carlsbad, CA, USA) and NOVA Biologics (Oceanside, CA, USA); 30 sera from patients with ovarian endometriosis were obtained from ProMedDx (Norton, MA, USA); and 30 sera from healthy women controls were purchased from SLR Research Corporation. These serum samples were biobank materials collected under IRB-approved protocol or as informed-consent donor samples. All samples were also stored at -80°C until use. The corresponding clinicopathological data are shown in Table 3.

*Real-time RT-PCR*—For mRNA expression analysis, total RNA was isolated from tissue samples and cell lines using the RNeasy Plus Micro Kit (Qiagen). The one step real-time RT-PCR analysis was carried out using the One-Step SYBR PrimeScript PLUS RT-PCR Kit according to the manufacturer's instructions. The analysis was performed using the Mx3000P Real-Time QPCR System (Agilent Technologies, Santa Clara, CA, USA). *TFPI2* mRNA levels were normalized against those of *ACTB* ( $\beta$ -actin). Primer sequences were as follows: *TFPI2*, 5'-TGGTTAGCAGGGAGGATTGC-3' (sense) and 5'-TCCGGATTCTACTGGCAAAG-3' (antisense);  $\beta$ -actin, 5'-GATGCAGAAGGAGATCACTGC-3' (sense) and 5'-ATACTCCTGCTTGCTGATCCAC-3' (antisense).

*Immunoprecipitation and Western blot*—Immunoprecipitation was conducted using mouse anti-TFPI2 monoclonal antibodies TF1-4 or TF1-6 (Tosoh Bioscience, Tokyo, Japan) with anti-mouse IgG-conjugated Dyna Magnet beads (Invitrogen). Immunoprecipitates were eluted in SDS-sample buffer and resolved by 12.5% SDS-PAGE. To detect TFPI2 protein, Western blots were carried out using the anti-TFPI2 28Aa mouse monoclonal antibody, which was raised against the *N*-terminal peptide of TFPI2 as described.<sup>17</sup> Anti-actin antibody I-19 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). These primary antibodies were detected with the peroxidase-conjugated anti-mouse IgG TrueBlot antibody (eBioscience, San Diego, CA), and visualized with enhanced chemiluminescence detection.

*TFPI2 and CA125 assays*—TFPI2 levels in samples were measured on an automated enzyme-linked immunosorbent assay (ELISA) system using a combination of anti-TFPI2 monoclonal antibodies, TF1-4 antibody conjugated with a magnet beads and TF1-6 antibody labeled with alkaline phosphatase. This is performed from binding reaction to fluorometric detection with an automated immunoassay analyzer system (Tosoh) as described previously.<sup>18</sup> The calibration standard for TFPI2 was prepared from the conditioned medium of HEK293-T cells transfected with the recombinant TFPI2 expression vector; the standard was spiked into FBS for the ELISA. Serum level of CA125 was assessed with a commercially available extracorporeal diagnostic kit, E test TOSOH II CA125 (Tosoh) according to the manufacture's instructions. Both automated ELISA were performed using the AIA-1800 analyzer machine (Tosoh). Results of each assay were confirmed to meet the following criteria: coefficient of variation (CV) less than 10%; measurement within the linear standard range; and  $R^2$  of the standard curve regression line at least 0.95.

*Statistical analysis*—ELISA data were plotted as a scatter plot and a receiver operating characteristic (ROC) curves. The statistical significance of the difference between two groups was determined using the Wilcoxon test. All data were processed using GraphPad PRISM software (version 5.0). Data are expressed as means  $\pm$  standard deviations.

## Results

### Secretome analysis

The workflow for secretome analysis is illustrated in Fig. 1. Four CCA cell lines and four cell lines derived from other types of EOC were cultured in serum-free media; 50–600 µg of protein were obtained from 20-mL samples of conditioned media. These protein samples were analyzed by LC-MS/MS as described above in Materials and Methods. Protein samples from CCA cell lines were individually examined **to find proteins common to these cell lines**. In the LC-MS/MS analyses, 3029–4514 unique peptides were identified from CCA cell lines, mapping to a total of 896–1231 unique proteins. **In addition, analyses of serous- and mucinous-type cell lines were also performed after pooling according to histological type, to reveal proteins which should not be selected as CCA-marker candidates.** In the pooled sample of the serous-type cell lines, OVSAHO and OVKATE, 3491–3702 unique peptides were identified, mapping to total of **1085** unique proteins; in the pooled sample of the mucinous-type cell lines, RMUG-S and MCAS, 3132–3197 unique peptides were identified, mapping to a total of 948 unique proteins. These data were summarized in **Supplementary Table S1, and the raw information (the peptide sequences, scores, the practical mass differences, etc.) was listed in Supplementary Table S2.**

### Selection of potential CCA marker candidate

To choose potential CCA marker candidates from among these proteins, we searched for proteins satisfying the following criteria.

First, we focused on proteins common to CCA cell lines, based on alignment of the LC-MS/MS analysis data. Of a total of 1864 proteins identified in CCA cell lines, 537 proteins

were present in all four cell lines, and 354 more proteins were present in three cell lines (Fig. 2A). This combined set of 891 proteins was chosen as the starting point.

Next, these 891 proteins were compared with proteins identified in cell lines derived from serous-type and mucinous-type EOC (Fig. 2B). This comparative analysis revealed that 148 proteins were restricted to CCA-derived cell lines. Several known EOC markers, including Mucin 16 (MUC16, a core protein of CA125) and cytokeratin 19 (KRT19, a core protein of CYFRA19-9),<sup>19</sup> were identified in all EOC cell lines. In addition,  $\beta_2$ -microglobulin (B2M), apolipoprotein A1 (APOA1), and transferrin (TF), which are biomarkers used in FDA-cleared OVA1 test,<sup>20</sup> and kallikrein-6 (KLK6),<sup>21</sup> were also detected in samples from serous- and mucinous-type cell lines. The restricted set of 148 proteins specific to CCA cell lines was expected to contain new biomarkers that might replace conventionally used general EOC markers.

From the list of 148 CCA-restricted proteins, we searched for those classified as extracellular proteins or membrane proteins, because these proteins or their fragments are more likely to enter the circulation and to be detectable in sera. For this purpose, we queried the 148 CCA-restricted proteins against the RCAI RefDIC database (<http://refdic.rcai.riken.jp/>). From this search, we identified 30 proteins classified by the Gene Ontology (GO) terms “extracellular space”, “extracellular region”, “cell surface”, and “plasma membrane”; several known biomarkers are also classified by such GO terms. Numbers of identified peptides and GO terms of known biomarkers and 30 CCA-specific biomarker candidates were summarized in [Table 1](#).

We further investigated the gene expression profiles of 30 proteins using the RefDIC database to identify proteins that are neither abundantly nor widely expressed in other tissues. Because tumor secretome proteins would be present at trace levels early in cancer progression, the most useful biomarkers would be those for which the baseline in healthy

individuals is as low as possible. In fact, gene expression patterns of several known biomarkers such as MUC16 (CA125), WFDC2 (HE4), or KLK3 (prostate cancer antigen, PSA) exhibit high tissue-specificity in the RefDIC database (Supplementary Figure S1). Of the 30 proteins, tissue factor pathway inhibitor 2 (TFPI2), which was identified in the OWISE, OVMANA, and OVSAYO cell lines, exhibited tissue-specific expression in a pattern similar to those of known biomarkers (Supplementary Figure S1). The Human Protein Atlas database (version 9.0, <http://www.proteinatlas.org/>) describes expression of TFPI2 as negative in most tissues but high in placenta (Supplementary Figure S2). In addition, a previous DNA microarray-based study that compared several subtypes of EOC reported *TFPI2* as a CCA-specific gene.<sup>22</sup> Thus, we focused our attention on TFPI2 as a potential biomarker for CCA.

### **CCA-specific expression of TFPI2 gene**

To verify the expression of *TFPI2* in CCA, we performed real-time RT-PCR analysis on the 8 EOC cell lines. This analysis revealed that the *TFPI2* transcript was highly expressed in every CCA-derived cell line except for OVTOKO (Fig. 3A). This result was consistent with the data from the aforementioned secretome analysis. Moreover, we also performed gene-expression analysis on 14 ovary tissue samples. *TFPI2* mRNA was also highly expressed in ovarian tissues from CCA patients, whereas it was barely detectable in patients with other EOC subtypes, benign tumors, or normal ovary tissue (Fig. 3B). These data indicate that *TFPI2* expression is specific to CCA.

### **TFPI2 secreted in conditioned media**

To detect TFPI2 secreted in conditioned media from CCA cell lines, we performed immunoprecipitations using the anti-TFPI2 monoclonal antibodies TF1-4 and TF1-6, which

were used as the capture antibody and detection antibody, respectively, in the automated ELISA system for TFPI2 detection. Immunoprecipitates brought down with TF1-4 or TF1-6 antibody and cell lysates were resolved on SDS-PAGE, and Western-blot analysis was carried out using a monoclonal antibody (28Aa) specific to the *N*-terminal 14 amino acid residues of TFPI2. As shown in Fig. 4A and B, three TFPI2 protein isoforms, thought to represent different glycosylated forms (33-kDa, 32-kDa, 27-kDa isoforms),<sup>23</sup> were detected in conditioned media and whole cell lysates from three CCA cell lines (OVISe, OVMANA, and OVSAYO). Moreover, automated ELISA also clearly detected TFPI2 in conditioned media from these CCA cell lines (Fig. 4C). The TFPI2 signals in cell lines markedly decreased upon introduction of TFPI2 siRNAs (data not shown), suggesting that the ELISA system was accurately detecting TFPI2. These results were consistent with the data from the secretome analysis and real-time RT-PCR analysis.

### **Serum levels of TFPI2 in CCA patients**

Because TFPI2 was specifically expressed in CCA-derived cell lines and tissues, and could be detected in conditioned media from these cell lines, we speculated that TFPI2 would be detectable in serum samples from CCA patients. To examine this possibility, we determined TFPI2 levels by automated ELISA in serum samples from patients with CCA ( $n = 50$ ), ovarian endometriosis ( $n = 30$ ), and healthy women ( $n = 30$ ), and compared TFPI2 levels to those of CA125 (Fig. 5A and B). **In the test set, serum CA125 levels were significantly higher in CCA patients (median [25th–75th percentiles], 219.5 [823.1–735.8] U/mL) than healthy women (17.0 [12.6–22.4] U/mL) or endometriosis patients (15.5 [7.2–24.0] U/mL). The levels of serum TFPI2 were also significantly higher in CCA patients (107.5 [35.2–183.0] ng/mL) compared to healthy women (<0.1 (below detection limit) [<0.1–1.2] ng/mL) or endometriosis samples (2.2 [1.5–3.0] ng/mL). TFPI2 levels in CCA patients were not**

statistically correlated with age or tumor stage (Fig. 5C and D). These findings support the use of TFPI2 as a novel biomarker for CCA detection.

### **Efficacy of TFPI2 and CA125 for CCA diagnosis**

To further evaluate the diagnostic efficacy of TFPI2, we conducted a receiver operating characteristic (ROC) curve analysis. The area under the ROC curves (AUC) for TFPI2 and CA125 were compared between CCA patients and either healthy controls or endometriosis patients. The analyses revealed that TFPI2 was superior to CA125 in discriminating CCA patients from healthy controls (AUC = 0.97 [95% CI, 0.94–1.00] versus AUC = 0.80 [95% CI, 0.70–0.90]; Fig. 6A) and endometriosis patients (AUC = 0.93 [95% CI, 0.88–1.00] versus AUC = 0.80 [95% CI, 0.71–0.90]; Fig. 6B). When a cutoff value of 12.3 ng/mL was chosen for TFPI2, the sensitivity and specificity of discrimination between CCA patients and healthy controls were 84% and 100%, respectively. For discrimination between CCA patients and endometriosis, sensitivity and specificity were 84% and 93%, respectively.

In general, patients with CCA have lower CA125 levels more frequently than patients with other EOC subtypes.<sup>7,8</sup> Of the 50 CCA patients in the test set, 13 patients had CA125 levels below 35 U/ml, the currently applied cutoff value for ovarian cancer screening. Applying a cutoff value 12.3 ng/mL for TFPI2, we found that 12 of 13 CCA patients with normal CA125 levels (<35 U/mL) were positive for TFPI2 (Fig. 6C). Collectively, these results indicate that the diagnostic accuracy of TFPI2 was higher than that of CA125.

### **Discussion**

EOC is a heterogeneous disease, and each histological subtype exhibits distinct clinical characteristics, morphology, and biological behavior.<sup>1</sup> Among EOC subtypes, CCA exhibits

a weaker response to standard platinum-based chemotherapy, and therefore has a markedly worse clinical prognosis. Furthermore, CCA cannot be reliably detected using CA125: whereas over 90% of patients with endometrioid-type and serous-type EOC show exhibit high levels of serum CA125, only 61% of patients with CCA are positive for this biomarker.<sup>7</sup> Therefore, identification of new biomarker is necessary in order to improve the detection efficiency of CCA and overcome the diagnostic limitations of CA125.

In the present study, we performed secretome analysis of cultured CCA-derived cell lines to identify optimal biomarker for CCA. We first examined proteins common to CCA cell lines by individual analysis of four cell lines (Fig. 2A). Then, we focused our attention on not only 537 proteins that were overlapped in all four CCA cell lines, but also 354 proteins that were identified only in three CCA cell lines, because we assumed that a cell line that decreased or lost gene expression of a useful marker candidate might be present. From the combined set of 891 proteins, we next eliminated proteins identified in cell lines derived from other types of EOC (Fig. 2B), and extracted “extracellular proteins” and “membrane proteins” using database information (Table 1). This analysis revealed that 30 proteins were specifically detected in conditioned media of CCA cell lines. Of these 30 proteins, only TFPI2 expression exhibited markedly higher tissue specificity in both mRNA (RefDIC) and protein (Human Protein Atlas) databases. In addition, a previous DNA microarray-based study suggests TFPI2 expression in ovarian tissues from CCA patients,<sup>22</sup> but there is no report on TFPI2 expression in blood samples from cancer patients. Thus, we focused our attention on TFPI2 as a new biomarker candidate for CCA diagnosis.

In our validation study, *TFPI2* mRNA was exclusively expressed in CCA-derived cell lines and tissues (Fig. 3), and secreted TFPI2 was also clearly detected in CCA cell lines except for OVTOKO cell line, in line with secretome analysis data (Fig. 4). TFPI2 assay using automated ELISA revealed that serum TFPI2 levels discriminated CCA patients not

only from healthy women, but also from patients with endometriosis (Fig. 5), with a higher diagnostic accuracy than that of CA125 (Fig. 6A and B). This is the first report that serum TFPI2 might be useful for CCA diagnosis. Although some secretome analyses aimed at discovery of potential serum biomarkers for ovarian cancer have already been reported,<sup>14</sup> very few of those reports discussed diagnostic accuracy for CCA. Importantly, we found that TFPI2 exhibited a higher rate (12/13) in CCA patients with normal levels of CA125 (Fig. 6C). Thus, use of TFPI2 as a biomarker might allow identification of CCA patients who are not diagnosed on the basis of CA125.

CCA is thought to arise, at least in part, from endometriosis; 50% of CCA and 40% of endometrioid-type ovarian cancers are associated with endometriosis.<sup>24</sup> Furthermore, endometriosis increases the risk of ovarian cancer, especially CCA.<sup>10</sup> Therefore, it is very important to carefully monitor the transformation from endometriosis into CCA. However, CA125 levels do not permit reliable monitoring, because this biomarker has low sensitivity in identifying patients with CCA (as well as early-stage EOC).<sup>6</sup> Furthermore, CA125 has a high false-positive rate in patients with endometriosis.<sup>25</sup> In contrast, serum TFPI2 levels could discriminate between patients with CCA and endometriosis with higher sensitivity (84%) and specificity (93%) than CA125. Thus, we believe that the use of TFPI2, alone or in combination with CA125, would improve the accuracy of CCA diagnosis.

TFPI2, also known as placental protein 5 (PP5),<sup>26,27</sup> is abundantly produced in placenta and can be detected in the serum of pregnant women.<sup>28</sup> Although the function of TFPI2 during pregnancy is not fully understood, serum TFPI2 level rises significantly during pregnancy.<sup>29,30</sup> In addition, TFPI2 level in maternal serum changes in cases of preeclampsia or intrauterine growth restriction.<sup>17</sup> Therefore, the TFPI2 level in pregnant women must be interpreted carefully. In this regard, TFPI2 is similar to CA125, the level of which is also influenced significantly by pregnancy.<sup>29</sup>

Although the physiological role of TFPI2 has yet to be firmly established, it has been reported that TFPI2 plays a role as a mitogen for vascular smooth muscle cells and retinal pigment epithelial cells.<sup>30,31</sup> In the context of cancer biology, study of TFPI2 has focused on its protease inhibitor activity. TFPI2 contains three tandemly repeated Kunitz-type proteinase inhibitory domains.<sup>32</sup> Due to its ability to inhibit a wide range of serine proteases, including plasmin, trypsin, or chymotrypsin, it may play a critical role in the regulation of extracellular matrix (ECM) remodeling.<sup>27, 33-35</sup> By broadly inhibiting proteases, TFPI2 may protect the ECM from degradation, thereby counteracting tumor invasion and metastasis. Consistently, many studies observed that overexpression of TFPI2 significantly suppresses cellular invasion or growth in several human cancer types, including lung, prostate, and pancreas.<sup>36-40</sup> TFPI2 has also been shown to induce apoptosis and inhibit angiogenesis.<sup>41,42</sup> Furthermore, TFPI2 expression is decreased or diminished upon aberrant methylation of the *TFPI2* promoter in various human cancers.<sup>40, 43-46</sup> Thus, it is reasonable to consider TFPI2 as a potential tumor suppressor. In this study, by contrast, we demonstrated that the *TFPI2* gene was exclusively expressed in CCA cell lines and tissues (Fig. 3). This finding is in agreement with a previous report, based on a DNA-microarray study, that the *TFPI2* gene is upregulated in CCA tissues relative to other histological subtype of EOC.<sup>22</sup> More patients with CCA are diagnosed during stage I than patients with other types of EOC.<sup>2</sup> Taken together, these observations suggest that TFPI2 helps to maintain CCA in the early stage by regulating the invasion and growth activity of the tumor cells.

In conclusion, we have identified the serine protease inhibitor TFPI2 as potential biomarker for CCA detection. An analysis of the area under the ROC curve showed that TFPI2 was superior to CA125 in discriminating CCA patients from healthy controls or patients with endometriosis. Although this finding awaits further validation in sera of

patients with other EOC subtypes and tumors from other tissues, TFPI2 nonetheless holds great promise as a diagnostic biomarker for CCA.

**SUPPORTING INFORMATION** Supplementary Table S1: Numbers of proteins identified in each sample. Supplementary Table S2: The raw information of protein identification. Supplementary Figure S1: Gene-expression profiles of conventional biomarkers and 30 CCA-specific biomarker candidates in the RefDIC database. Supplementary Figure S2: Expression profile of TFPI2 in the Human Protein Atlas using CAB10142 antibody. This material is available free of charge via the Internet at <http://pubs.acs.org>.

**ACKNOWLEDGEMENT** This work was supported in part by the Special Coordination Funds for Promoting Science and Technology “Creation of Innovation Centers for Advanced Interdisciplinary Research Areas” (to H.H.), and in part by Grants-in-Aid, Research on Biological Markers for New Drug Development H20-0005 (to H.H.), and Grant-in-Aid for young Scientists (B) 22790530 from The Ministry of Education, Culture, Sports, Science and Technology (to N.A.) of Japan.

## REFERENCES

1. Cho, K. R.; Shih Ie, M., Ovarian cancer. *Annual review of pathology* 2009, 4, 287-313.
2. Itamochi, H.; Kigawa, J.; Terakawa, N., Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. *Cancer science* 2008, 99, (4), 653-8.
3. Sugiyama, T.; Kamura, T.; Kigawa, J.; Terakawa, N.; Kikuchi, Y.; Kita, T.; Suzuki, M.; Sato, I.; Taguchi, K., Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. *Cancer* 2000, 88, (11), 2584-9.
4. Itamochi, H.; Kigawa, J.; Akeshima, R.; Sato, S.; Kamazawa, S.; Takahashi, M.; Kanamori, Y.; Suzuki, M.; Ohwada, M.; Terakawa, N., Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. *Oncology* 2002, 62, (4), 349-53.
5. Itamochi, H.; Kigawa, J.; Sugiyama, T.; Kikuchi, Y.; Suzuki, M.; Terakawa, N., Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. *Obstetrics and gynecology* 2002, 100, (2), 281-7.
6. Suh, K. S.; Park, S. W.; Castro, A.; Patel, H.; Blake, P.; Liang, M.; Goy, A., Ovarian cancer biomarkers for molecular biosensors and translational medicine. *Expert review of molecular diagnostics* 2010, 10, (8), 1069-83.
7. Kudoh, K.; Kikuchi, Y.; Kita, T.; Tode, T.; Takano, M.; Hirata, J.; Mano, Y.; Yamamoto, K.; Nagata, I., Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. *Gynecologic and obstetric investigation* 1999, 47, (1), 52-7.

8. Pectasides, D.; Fountzilas, G.; Aravantinos, G.; Kalofonos, C.; Efstathiou, H.; Farmakis, D.; Skarlos, D.; Pavlidis, N.; Economopoulos, T.; Dimopoulos, M. A., Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. *Gynecologic oncology* 2006, 102, (2), 285-91.
9. Meyer, T.; Rustin, G. J., Role of tumour markers in monitoring epithelial ovarian cancer. *British journal of cancer* 2000, 82, (9), 1535-8.
10. Nagle, C. M.; Olsen, C. M.; Webb, P. M.; Jordan, S. J.; Whiteman, D. C.; Green, A. C., Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. *European journal of cancer* 2008, 44, (16), 2477-84.
11. Morita, A.; Miyagi, E.; Yasumitsu, H.; Kawasaki, H.; Hirano, H.; Hirahara, F., Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. *Proteomics* 2006, 6, (21), 5880-90.
12. Kim, A.; Enomoto, T.; Serada, S.; Ueda, Y.; Takahashi, T.; Ripley, B.; Miyatake, T.; Fujita, M.; Lee, C. M.; Morimoto, K.; Fujimoto, M.; Kimura, T.; Naka, T., Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. *International journal of cancer. Journal international du cancer* 2009, 125, (10), 2316-22.
13. Anderson, N. L.; Anderson, N. G.; Haines, L. R.; Hardie, D. B.; Olafson, R. W.; Pearson, T. W., Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). *Journal of proteome research* 2004, 3, (2), 235-44.
14. Makridakis, M.; Vlahou, A., Secretome proteomics for discovery of cancer biomarkers. *Journal of proteomics* 2010, 73, (12), 2291-305.

15. Gorai, I.; Nakazawa, T.; Miyagi, E.; Hirahara, F.; Nagashima, Y.; Minaguchi, H., Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. *Gynecologic oncology* 1995, 57, (1), 33-46.
16. Yanagibashi, T.; Gorai, I.; Nakazawa, T.; Miyagi, E.; Hirahara, F.; Kitamura, H.; Minaguchi, H., Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20. *British journal of cancer* 1997, 76, (7), 829-35.
17. Ogawa, M.; Yanoma, S.; Nagashima, Y.; Okamoto, N.; Ishikawa, H.; Haruki, A.; Miyagi, E.; Takahashi, T.; Hirahara, F.; Miyagi, Y., Paradoxical discrepancy between the serum level and the placental intensity of PP5/TFPI-2 in preeclampsia and/or intrauterine growth restriction: possible interaction and correlation with glypican-3 hold the key. *Placenta* 2007, 28, (2-3), 224-32.
18. Nakamura, K.; Igarashi, K.; Ide, K.; Ohkawa, R.; Okubo, S.; Yokota, H.; Masuda, A.; Oshima, N.; Takeuchi, T.; Nangaku, M.; Okudaira, S.; Arai, H.; Ikeda, H.; Aoki, J.; Yatomi, Y., Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. *Clinica chimica acta; international journal of clinical chemistry* 2008, 388, (1-2), 51-8.
19. Gadducci, A.; Ferdeghini, M.; Cosio, S.; Fanucchi, A.; Cristofani, R.; Genazzani, A. R., The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society* 2001, 11, (4), 277-82.
20. Fung, E. T., A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. *Clinical chemistry* 2010, 56, (2), 327-9.

21. Luo, L. Y.; Soosaipillai, A.; Grass, L.; Diamandis, E. P., Characterization of human kallikreins 6 and 10 in ascites fluid from ovarian cancer patients. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine* 2006, 27, (5), 227-34.
22. Zorn, K. K.; Bonome, T.; Gangi, L.; Chandramouli, G. V.; Awtrey, C. S.; Gardner, G. J.; Barrett, J. C.; Boyd, J.; Birrer, M. J., Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2005, 11, (18), 6422-30.
23. Rao, C. N.; Reddy, P.; Liu, Y.; O'Toole, E.; Reeder, D.; Foster, D. C.; Kisiel, W.; Woodley, D. T., Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. *Archives of biochemistry and biophysics* 1996, 335, (1), 82-92.
24. Sato, N.; Tsunoda, H.; Nishida, M.; Morishita, Y.; Takimoto, Y.; Kubo, T.; Noguchi, M., Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. *Cancer research* 2000, 60, (24), 7052-6.
25. Markman, M., CA-125: an evolving role in the management of ovarian cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 1996, 14, (5), 1411-2.

26. Kisiel, W.; Sprecher, C. A.; Foster, D. C., Evidence that a second human tissue factor pathway inhibitor (TFPI-2) and human placental protein 5 are equivalent. *Blood* 1994, 84, (12), 4384-5.
27. Miyagi, Y.; Koshikawa, N.; Yasumitsu, H.; Miyagi, E.; Hirahara, F.; Aoki, I.; Misugi, K.; Umeda, M.; Miyazaki, K., cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2. *Journal of biochemistry* 1994, 116, (5), 939-42.
28. Bohn, H.; Winckler, W., [Isolation and characterization of the placental protein pp5 (author's transl)]. *Archiv fur Gynakologie* 1977, 223, (3), 179-86.
29. Sarandakou, A.; Protonotariou, E.; Rizos, D., Tumor markers in biological fluids associated with pregnancy. *Critical reviews in clinical laboratory sciences* 2007, 44, (2), 151-78.
30. Shinoda, E.; Yui, Y.; Hattori, R.; Tanaka, M.; Inoue, R.; Aoyama, T.; Takimoto, Y.; Mitsui, Y.; Miyahara, K.; Shizuta, Y.; Sasayama, S., Tissue factor pathway inhibitor-2 is a novel mitogen for vascular smooth muscle cells. *The Journal of biological chemistry* 1999, 274, (9), 5379-84.
31. Tanaka, Y.; Utsumi, J.; Matsui, M.; Sudo, T.; Nakamura, N.; Mutoh, M.; Kajita, A.; Sone, S.; Kigasawa, K.; Shibuya, M.; Reddy, V. N.; Zhang, Q.; Iwata, T., Purification, molecular cloning, and expression of a novel growth-promoting factor for retinal pigment epithelial cells, REF-1/TFPI-2. *Investigative ophthalmology & visual science* 2004, 45, (1), 245-52.
32. Bajaj, M. S.; Birktoft, J. J.; Steer, S. A.; Bajaj, S. P., Structure and biology of tissue factor pathway inhibitor. *Thrombosis and haemostasis* 2001, 86, (4), 959-72.

33. Sprecher, C. A.; Kisiel, W.; Mathewes, S.; Foster, D. C., Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. *Proceedings of the National Academy of Sciences of the United States of America* 1994, 91, (8), 3353-7.
34. Rao, C. N.; Liu, Y. Y.; Peavey, C. L.; Woodley, D. T., Novel extracellular matrix-associated serine proteinase inhibitors from human skin fibroblasts. *Archives of biochemistry and biophysics* 1995, 317, (1), 311-4.
35. Petersen, L. C.; Sprecher, C. A.; Foster, D. C.; Blumberg, H.; Hamamoto, T.; Kisiel, W., Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. *Biochemistry* 1996, 35, (1), 266-72.
36. Lakka, S. S.; Konduri, S. D.; Mohanam, S.; Nicolson, G. L.; Rao, J. S., In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2. *Clinical & experimental metastasis* 2000, 18, (3), 239-44.
37. Konduri, S. D.; Tasiou, A.; Chandrasekar, N.; Rao, J. S., Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. *International journal of oncology* 2001, 18, (1), 127-31.
38. Konduri, S. D.; Rao, C. N.; Chandrasekar, N.; Tasiou, A.; Mohanam, S.; Kin, Y.; Lakka, S. S.; Dinh, D.; Olivero, W. C.; Gujrati, M.; Foster, D. C.; Kisiel, W.; Rao, J. S., A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. *Oncogene* 2001, 20, (47), 6938-45.
39. Yanamandra, N.; Kondraganti, S.; Gondi, C. S.; Gujrati, M.; Olivero, W. C.; Dinh, D. H.; Rao, J. S., Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits

invasion, angiogenesis and tumor growth in a human glioblastoma cell line. *International journal of cancer. Journal international du cancer* 2005, 115, (6), 998-1005.

40. Sato, N.; Parker, A. R.; Fukushima, N.; Miyagi, Y.; Iacobuzio-Donahue, C. A.; Eshleman, J. R.; Goggins, M., Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. *Oncogene* 2005, 24, (5), 850-8.

41. George, J.; Gondi, C. S.; Dinh, D. H.; Gujrati, M.; Rao, J. S., Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. *Clinical cancer research : an official journal of the American Association for Cancer Research* 2007, 13, (12), 3507-17.

42. Ran, Y.; Pan, J.; Hu, H.; Zhou, Z.; Sun, L.; Peng, L.; Yu, L.; Liu, J.; Yang, Z., A novel role for tissue factor pathway inhibitor-2 in the therapy of human esophageal carcinoma. *Human gene therapy* 2009, 20, (1), 41-9.

43. Konduri, S. D.; Srivenugopal, K. S.; Yanamandra, N.; Dinh, D. H.; Olivero, W. C.; Gujrati, M.; Foster, D. C.; Kisiel, W.; Ali-Osman, F.; Kondraganti, S.; Lakka, S. S.; Rao, J. S., Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. *Oncogene* 2003, 22, (29), 4509-16.

44. Rao, C. N.; Segawa, T.; Navari, J. R.; Xu, L.; Srivastava, S.; Moul, J. W.; Phillips, B., Methylation of TFPI-2 gene is not the sole cause of its silencing. *International journal of oncology* 2003, 22, (4), 843-8.

45. Sierko, E.; Wojtukiewicz, M. Z.; Kisiel, W., The role of tissue factor pathway inhibitor-2 in cancer biology. *Seminars in thrombosis and hemostasis* 2007, 33, (7), 653-9.

46. Steiner, F. A.; Hong, J. A.; Fischette, M. R.; Beer, D. G.; Guo, Z. S.; Chen, G. A.; Weiser, T. S.; Kassis, E. S.; Nguyen, D. M.; Lee, S.; Trepel, J. B.; Schrupp, D. S., Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. *Oncogene* 2005, 24, (14), 2386-97.

## FIGURE LEGENDS

**Figure 1.** Secretome-based differential analysis of ovarian cancer cell lines. Experimental overview. Protein samples from CCA cell lines were individually examined, and those from serous- and mucinous-type EOC cell lines were analyzed after pooling according to each histological subtype. Total numbers of proteins identified from each sample were indicated.

**Figure 2.** Overlaps of proteins identified between each sample. Venn diagrams show overlap between four CCA cell lines (A), and between the 891 proteins common to CCA cell lines and the set of proteins identified in serous- and mucinous-type EOC cell lines (B). This illustration indicates the categories that include known ovarian cancer markers and TFPI2 were identified. Asterisks indicate the biomarkers used in the OVA1 test.

**Figure 3.** CCA-specific expression of TFPI2 gene. *TFPI2* mRNA levels in ovarian cancer cell lines (A) and various ovarian tissue samples (B) were evaluated by real-time PCR. Data were normalized against  $\beta$ -actin mRNA levels. The corresponding clinicopathological data from these tissue samples are shown in Table 2.

**Figure 4.** Detection of secreted TFPI2 in condition media. TFPI2 in conditioned media (CM, A) and whole-cell lysate (WCL, B) were detected by Western blot. Aliquots of conditioned media (0.5 mL) were subjected to immunoprecipitation with either TF1-6 or TF1-4 monoclonal antibodies. Precipitates or whole-cell lysates were resolved by denaturing SDS-PAGE, and TFPI2 was detected by Western blot using the 28aA anti-TFPI2 monoclonal

antibody. (C) TFPI2 in conditioned media was determined using an automated ELISA system.

**Figure 5.** Serum levels of CA125 and TFPI2 in CCA patients. The serum levels of CA125 (A) and TFPI2 (B) were measured in 50 CCA patients, 30 endometriosis patients (Em), and 30 healthy controls (Cont.). The corresponding clinicopathological data from these serum samples are summarized in Table 3. (C, D) Serum TFPI2 levels in CCA patients, grouped by age (C) and tumor stage (D). Middle horizontal line indicates the median; upper and lower lines indicate the 25<sup>th</sup> and 75<sup>th</sup> percentiles of the data range, respectively. TFPI2 levels under detection limit (0.1 ng/mL) were represented as 0.1 ng/mL.

**Figure 6.** Efficacy of TFPI2 for CCA detection. (A, B) ROC curve analyses of the ability of CA125 and TFPI2 to discriminate between healthy controls and CCA patients (A), and between endometriosis and CCA patients (B). (C) TFPI2 levels in sera from 13 patients with normal CA125 levels (<35 U/mL). Cutoff values of CA125 (35 U/mL) and TFPI2 (12.3 ng/mL) are indicated with lines.

## TABLES with LEGEND

**Table 1.** Numbers of unique peptides identified and extracted GO terms of conventional serum biomarkers and 30 CCA-specific biomarker candidates.

Uniprot accession	Gene symbol	Protein name	Unique peptides						Extracted GO terms (Cellular Component)
			Clear cell			Serous	Mucinous	OVSAHO, RMUGS, OVKATE MCAS	
			OVTOKO	OVISE	OVMANA	OVSAHO	OVSAHO		
<b>Known biomarker</b>									
P02647	<i>APOA1</i>	Apolipoprotein A-1	1	1	1	1	1	7	extracellular region, extracellular space, plasma membrane
P61769	<i>B2M</i>	Beta-2-microglobulin	2	4	3	4	4	4	extracellular region, extracellular space, plasma membrane
Q92876	<i>KLK6</i>	Kallikrein-6	-	10	-	11	11	6	extracellular region
P08727	<i>KRT19</i>	Keratin, type I cytoskeletal 19	-	10	13	16	19	3	other GO terms
Q8WX17	<i>MUC16</i>	Mucin-16	1	2	1	17	4	10	extracellular region, extracellular space, plasma membrane,
P02787	<i>TF</i>	Serotransferrin	1	1	-	-	3	3	extracellular region
P02766	<i>TTR</i>	Transthyretin	-	-	-	-	-	-	extracellular region
Q14508	<i>WFDC2</i>	WAP four-disulfide core domain protein 2	-	-	-	-	-	2	extracellular region, extracellular space
P07288	<i>KLK3</i>	Prostate-specific antigen	-	-	-	-	-	-	extracellular region
<b>CCA-specific biomarker candidates</b>									
Q9UHI8	<i>ADAMTS1</i>	A disintegrin and metalloproteinase with thrombospondin motifs 1	2	1	-	3	-	-	extracellular region
Q86SJ2	<i>AMIGO2</i>	Amphoterin-induced protein 2	5	2	-	1	-	-	plasma membrane
P18085	<i>ARF4</i>	ADP-ribosylation factor 4	-	1	1	2	-	-	plasma membrane
P54709	<i>ATP1B3</i>	Sodium/potassium-transporting ATPase subunit beta-3	-	1	1	1	-	-	plasma membrane
P43251	<i>BTD</i>	Biotinidase	5	2	-	2	-	-	extracellular space, extracellular region
Q9Y5K6	<i>CD2AP</i>	CD2-associated protein	-	4	2	1	-	-	plasma membrane
O95832	<i>CLDN1</i>	Claudin-1	1	1	1	2	-	-	plasma membrane
O60610	<i>DIAPH1</i>	Protein diaphanous homolog 1	-	1	2	1	-	-	plasma membrane
Q6E0U4	<i>DMKN</i>	Dermokine	-	4	3	2	-	-	extracellular space, extracellular region
Q9NZ08	<i>ERAP1</i>	Endoplasmic reticulum aminopeptidase 1	7	3	5	5	-	-	extracellular region
P54652	<i>HSPA2</i>	Heat shock-related 70 kDa protein 2	1	2	1	3	-	-	cell surface
P05231	<i>IL6</i>	Interleukin-6	5	9	4	-	-	-	extracellular space, extracellular

								region	
P78504	<i>JAG1</i>	Protein jagged-1	-	2	1	2	-	-	extracellular region, plasma membrane
Q9UIQ6	<i>LNPEP</i>	Leucyl-cystinyl aminopeptidase	-	1	1	1	-	-	extracellular region, plasma membrane
Q13564	<i>NAE1</i>	NEDD8-activating enzyme E1 regulatory subunit	1	1	1	2	-	-	plasma membrane
Q92597	<i>NDRG1</i>	Protein NDRG1	2	2	1	1	-	-	plasma membrane
Q14112	<i>NID2</i>	Nidogen-2	30	43	37	34	-	-	extracellular region
Q8IV19	<i>NOSTRIN</i>	Nostrin	1	1	1	1	-	-	plasma membrane
Q92823	<i>NRCAM</i>	Neuronal cell adhesion molecule	3	3	9	13	-	-	plasma membrane
Q9NVD7	<i>PARVA</i>	Alpha-parvin	1	1	1	-	-	-	plasma membrane
Q13162	<i>PRDX4</i>	Peroxiredoxin-4	-	5	2	3	-	-	extracellular space, extracellular region
Q15907	<i>RAB11B</i>	Ras-related protein Rab-11B	-	2	2	3	-	-	plasma membrane
P51148	<i>RAB5C</i>	Ras-related protein Rab-5C	-	3	2	1	-	-	plasma membrane
P61006	<i>RAB8A</i>	Ras-related protein Rab-5C	-	2	1	1	-	-	plasma membrane
Q96QD8	<i>SLC38A2</i>	Sodium-coupled neutral amino acid transporter 2	-	1	1	1	-	-	plasma membrane
Q00796	<i>SORD</i>	Sorbitol dehydrogenase	-	2	1	3	-	-	extracellular space
Q15833	<i>STXBP2</i>	Syntaxin-binding protein 2	-	1	1	1	-	-	plasma membrane
P20062	<i>TCN2</i>	Transcobalamin-2	7	-	4	11	-	-	extracellular space, extracellular region
P48307	<i>TFPI2</i>	Tissue factor pathway inhibitor 2	-	5	8	1	-	-	extracellular region
P98155	<i>VLDLR</i>	Very low-density lipoprotein receptor	5	6	3	13	-	-	extracellular space, plasma membrane

**Table 2.** Clinicopathological characteristics of tissue samples.

Sample ID	Source	Age (years)	Tissue types	Clinical Stages
1	Ambion	92	normal	--
2	Zyagen	46	normal	--
3	YCU*	27	simple cyst adenoma	--
4	YCU*	47	mucinous cyst adenoma	--
5	YCU*	56	serous cyst adenoma	--
6	YCU*	39	mature teranoma	--
7	YCU*	67	mucinous adenocarcinoma	3 c
8	YCU*	31	mucinous adenocarcinoma	1a
9	YCU*	45	serous adenocarcinoma	3c
10	YCU*	54	serous adenocarcinoma	2c
11	YCU*	54	CCA	1 a
12	YCU*	62	CCA	3c
13	YCU*	42	CCA	1c
14	YCU*	55	CCA	1a

\*YCU = Yokohama City University Hospital

**Table 3.** Clinicopathological characteristics of serum samples.

Characteristics	Healthy woman controls (n = 30)	Endometriosis (n = 30)	CCA (n = 50)
<b>Biobank</b>			
SLR Research	30	--	30
ProMedDx	--	30	--
NOVA Biologics	--	---	20
<b>Age (years)</b>			
≤39	17	13	0
40≤49	8	16	9
50≤59	5	1	25
≥60	0	0	16
mean age (range)	38.3 (24-51)	39.7 (30-56)	56.8 (42-71)
<b>Classification</b>			
		rAFS	FIGO
Stage I	--	5	15
Stage II	--	11	28
Stage III	--	9	7
Stage IV	--	5	0
Total number	30	30	50

## Supporting Information

### Supplementary Figure Legends

**Supplementary Figure S1.** Gene-expression profiles of conventional biomarkers (A) and 30 CCA-specific biomarker candidates (B) in the RefDIC database. Known biomarkers and biomarker candidates are displayed by their gene symbols. The expression profiles were processed using the RCAI RefDIC database, based on the following criteria: profile type, microarray; data set, Affymetrix Human U133 Plus 2.0 array; and query type, gene symbol. Representative data of probes with rank A is displayed, except for *WFDC2*, which does not have rank-A probe data.

**Supplementary Figure S2.** Expression profile of TFPI2 in the Human Protein Atlas using CAB10142 antibody. Expression profile of TFPI2 in various normal tissues, based on immunohistochemical studies, from the Human Protein Atlas database ver. 10.0 (<http://www.proteinatlas.org/ENSG00000105825/normal>).

## Supplementary Table Legends

**Supplementary Table S1.** Numbers of proteins identified in each sample.

**Supplementary Table S2.** **The raw information of protein identification.** The raw information for all identified peptides is displayed, including the sources, distinct sequences, coverage, numbers of unique peptides, theoretical masses, and practical average masses. Data were processed using Proteome Discoverer 1.3 software (Thermo Scientific) with Mascot ver. 2.3.02 (Matrix Science, London, UK).